Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit
March 17 2022 - 7:00AM
Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the
"Company”), today announced that Michael J. Newman, Ph.D., Founder
and Chief Scientific Officer, will present and participate in a
panel discussion at the 3rd Annual STING & TLR-Targeting
Therapies Summit taking place virtually from March 22-24, 2022.
Presentation Details:
- Title: Eradication of Established Tumors with
Induction of Innate & Adaptive Immunological Memory in Multiple
Preclinical Models with Systemically Administered Decoy Bacteria, a
Multi-TLR Agonist Therapeutic Vaccine
- Date/Time: March 24, 2022 at 11:30 AM ET
Panel Discussion Details:
- Title: What is the Best Modality &
Delivery Approach to PRR-Pathway Targeting?
- Date/Time: March 24, 2022 at 1:30 PM ET
The 3rd STING & TLR-Targeting Therapies Summit is dedicated
to progressing the therapeutic modulation of the innate-adaptive
immune axis, turning “cold” tumors “hot”, recruiting activated
tumor-specific T-cells and generating localized and systemic
anti-tumor responses.
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than
a century of immunotherapy advances. The Company's approach is
based on the hypothesis that efficient activation of both innate
and adaptive immune cells and associated anti-tumor and anti-viral
immune responses will require a multi-targeted package of immune
system activating signals that can be administered safely
intravenously. Indaptus' patented technology is composed of single
strains of attenuated and killed, non-pathogenic, Gram-negative
bacteria, with reduced i.v. toxicity, but largely uncompromised
ability to prime or activate many of the cellular components of
innate and adaptive immunity. This approach has led to broad
anti-tumor and anti-viral activity, including safe, durable
anti-tumor response synergy with each of five different classes of
existing agents, including checkpoint therapy, targeted antibody
therapy and low-dose chemotherapy in preclinical models. Tumor
eradication by Indaptus technology has been demonstrated to produce
both innate and adaptive immunological memory and, importantly,
does not require provision of or targeting a specific tumor antigen
in pre-clinical models. Indaptus has carried out successful GMP
manufacturing of its lead clinical oncology candidate, Decoy20, and
has completed other IND enabling studies.
Forward-Looking Statements
This press release contains forward-looking
statements with the meaning of the Private Securities Litigation
Reform Act. These include statements regarding management's
expectations, beliefs and intentions regarding, among other things,
our product development efforts, business, financial condition,
results of operations, strategies, plans and prospects.
Forward-looking statements can be identified by the use of
forward-looking words such as "believe", "expect", "intend",
"plan", "may", "should", "could", "might", "seek", "target",
"will", "project", "forecast", "continue" or "anticipate" or their
negatives or variations of these words or other comparable words or
by the fact that these statements do not relate strictly to
historical matters. Forward-looking statements relate to
anticipated or expected events, activities, trends or results as of
the date they are made. Because forward-looking statements relate
to matters that have not yet occurred, these statements are
inherently subject to risks and uncertainties that could cause our
actual results to differ materially from any future results
expressed or implied by the forward-looking statements. Many
factors could cause actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements, including, but not limited to, the
following: Indaptus' plans to develop and potentially commercialize
its technology, the timing and cost of Indaptus' planned
investigational new drug application and any clinical trials, the
completion and receiving favorable results in any clinical trials,
Indaptus' ability to obtain and maintain regulatory approval of any
product candidate, Indaptus' ability to protect and maintain its
intellectual property and licensing arrangements, Indaptus' ability
to develop, manufacture and commercialize its product candidates,
the risk of product liability claims, the availability of
reimbursement, the influence of extensive and costly government
regulation, and Indaptus' estimates regarding future revenue,
expenses capital requirements and the need for additional financing
following the merger. These risks, as well as other risks are
discussed in the proxy statement/prospectus that was included in
the registration statement on Form S-4 filed with the SEC in
connection with the merger. All forward-looking statements speak
only as of the date of this press release and are expressly
qualified in their entirety by the cautionary statements included
in this press release. We undertake no obligation to update or
revise forward-looking statements to reflect events or
circumstances that arise after the date made or to reflect the
occurrence of unanticipated events, except as required by
applicable law.
Investor Contact:Will O'ConnorStern Investor
Relations+1 212-362-1200will.oconnor@sternir.com
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jul 2023 to Jul 2024